Management and treatment of glomerular diseases (part 2): Conclusions From A Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference

Rovin, Brad H.; Caster, Dawn J.; Cattran, Daniel C.; Gibson, Keisha; Hogan, Jonathan J.; Moeller, Marcus J.; Roccatello, Dario; Cheung, Michael; Wheeler, David C.; Winkelmayer, Wolfgang C.; Floege, Jürgen

doi:10.36485/1561-6274-2021-25-1-96-119

Cited by 27 publications

(61 citation statements)

References 221 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…First episode of nephrotic syndrome in children-weight-based prednisolone (1.5 mg/kg [maximum 40 mg]) versus body-surface area-based dosing of prednisolone (40 mg/m 2 ) Table S136. First episode of nephrotic syndrome in children-higher total dose (60 mg/m 2 /d [max 80 mg] for 6 weeks, 40 mg/m 2 on alternate days for 6 weeks) prednisone versus lower total dose (40 mg/m 2 / d [max 60 mg] for 6 weeks, 40 mg/m 2 on alternate days for 6 weeks) prednisone Table S137. First episode of nephrotic syndrome in children-deflazacort versus prednisolone Table S138.…”

Section: S7mentioning

confidence: 99%

“…Patients with HIV-associated nephropathy-glucocorticoids and antiretroviral therapy versus antiretroviral therapy only Chapter 8: Immunoglobulin-and complement-mediated glomerular diseases with a membranoproliferative glomerulonephritis (MPGN) pattern of injury Table S186. Children with idiopathic membranoproliferative glomerulonephritis-prednisone 40 mg/m 2 (alternate day) versus placebo Table S187. Observational studies-treatment of idiopathic membranoproliferative glomerulonephritis Table S188.…”

Section: S7mentioning

confidence: 99%

“…The conclusions from this Controversies Conference were published in Kidney International last year. 1,2 Based on this conference, a guideline update was recommended.…”

Section: Very Lowmentioning

confidence: 99%

Section: Assessment Of Kidney Functionmentioning

confidence: 99%

“…20 Please refer to the KDIGO CKD guideline for more information. 18 1 Perrone et al 13 , 2 Gaspari et al 12 , 3 Cockcroft and Gault. 11 , 4 Stevens et al 16 , 5 Stevens et al 17 , 6 Schwartz et al 15 , 7 Pottel et al 14 , Estimation of GFR using the CKD-EPI formula based on SCr has gained increasing acceptance, although it has not been validated specifically in those patients with GN.…”

Section: Estimation Of Gfrmentioning

confidence: 99%

See 4 more Smart Citations

KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases

Rovin¹,

Adler²,

Barratt³

et al. 2021

Kidney International

Self Cite

889

688

View full text Add to dashboard Cite

S28 Introduction S30 Summary of recommendation statements and practice points S88 Chapter 1: General principles for the management of glomerular disease S115 Chapter 2: Immunoglobulin A nephropathy (IgAN)/immunoglobulin A vasculitis (IgAV) S128 Chapter 3: Membranous nephropathy S140 Chapter 4: Nephrotic syndrome in children S153 Chapter 5: Minimal change disease (MCD) in adults S161 Chapter 6: Focal segmental glomerulosclerosis (FSGS) in adults S172 Chapter 7: Infection-related glomerulonephritis S187 Chapter 8: Immunoglobulin-and complement-mediated glomerular diseases with a membranoproliferative glomerulonephritis (MPGN) pattern of injury S193 Chapter 9: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis S207 Chapter 10: Lupus nephritis S231 Chapter 11: Anti-glomerular basement membrane (Anti-GBM) antibody glomerulonephritis S235 Methods for guideline development S243 Biographic and disclosure information S254 Acknowledgments S256 ReferencesThis guideline is published as a supplement supported by KDIGO. The development and publication of this guideline are strictly funded by KDIGO, and neither KDIGO nor its guideline Work Group members sought or received monies or fees from corporate or commercial entities in connection with this work. The opinions or views expressed in this professional education supplement are those of the authors and do not necessarily reflect the opinions or recommendations of the International Society of Nephrology or Elsevier. Dosages, indications, and methods of use for products that are referred to in the supplement by the authors may reflect their clinical experience or may be derived from the professional literature or other clinical sources. Because of the differences between in vitro and in vivo systems and between laboratory animal models and clinical data in humans, in vitro and animal data may not necessarily correlate with clinical results.

show abstract

Section: S7mentioning

confidence: 99%

Section: S7mentioning

confidence: 99%

“…The conclusions from this Controversies Conference were published in Kidney International last year. 1,2 Based on this conference, a guideline update was recommended.…”

Section: Very Lowmentioning

confidence: 99%

Section: Assessment Of Kidney Functionmentioning

confidence: 99%

Section: Estimation Of Gfrmentioning

confidence: 99%

See 3 more Smart Citations

KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases

Rovin¹,

Adler²,

Barratt³

et al. 2021

Kidney International

Self Cite

889

688

View full text Add to dashboard Cite

show abstract

Consensus Treatment Plans for Severe Pediatric Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

Morishita

Wagner‐Weiner

Yen

et al. 2022

Arthritis Care & Research

View full text Add to dashboard Cite

for the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Antineutrophil Cytoplasmic Antibody-Associated Vasculitis WorkgroupObjective. There is no standardized approach to the treatment of pediatric antineutrophil cytoplasmic antibodyassociated vasculitis (AAV). Because of the rarity of pediatric AAV, randomized trials have not been feasible. The present study of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) was undertaken to establish consensus treatment plans (CTPs) for severe pediatric AAV to enable the future study of comparative effectiveness and safety.Methods. A workgroup of CARRA members (rheumatologists and nephrologists) formed the AAV Workgroup. This group performed a literature review on existing evidence-based treatments and guidelines for the management of AAV. They determined that the target population for CTP development was patients <18 years of age with new-onset granulomatosis with polyangiitis (GPA), microscopic polyangiitis, or renal-limited AAV (eosinophilic GPA was excluded), with presentation confined to those with severe disease (i.e., organ-or life-threatening). Face-to-face consensus conferences employed nominal group techniques to identify treatment strategies for remission induction and remission maintenance, data elements to be systematically collected, and outcomes to be measured over time.Results. The pediatric AAV Workgroup developed 2 CTPs for each of the remission induction and remission maintenance of severe AAV. A glucocorticoid-weaning regimen for induction and maintenance, a core data set, and outcome measures were also defined. A random sample of CARRA membership voted acceptance of the CTPs for remission induction and remission maintenance, with a 94% (75 of 80) and 98% (78 of 80) approval rate, respectively.Conclusion. Consensus methodology established standardized CTPs for treating severe pediatric AAV. These CTPs were in principle accepted by CARRA-wide membership for the evaluation of pragmatic comparative effectiveness in a long-term registry.

show abstract

Development of American College of Rheumatology Quality Measures for Systemic Lupus Erythematosus: A Modified Delphi Process With Rheumatology Informatics System for Effectiveness (RISE) Registry Data Review

Bartels

Jorge

Feldman

et al. 2023

Arthritis Care & Research

View full text Add to dashboard Cite

ObjectiveWe aimed to develop readily measurable digital quality measure statements for clinical care in systemic lupus erythematosus (SLE) using a multistep process guided by consensus methods.MethodsUsing a modified Delphi process, an American College of Rheumatology (ACR) workgroup of SLE experts reviewed all North American and European guidelines from 2000 to 2020 on treatment, monitoring, and phenotyping of patients with lupus. Workgroup members extracted quality constructs from guidelines, rated these by importance and feasibility, and generated evidence‐based quality measure statements. The ACR Rheumatology Informatics System for Effectiveness (RISE) Registry was queried for measurement data availability. In 3 consecutive Delphi sessions, a multidisciplinary Delphi panel voted on the importance and feasibility of each statement. Proposed measures with consensus on feasibility and importance were ranked to identify the top 3 measures.ResultsReview of guidelines and distillation of 57 quality constructs resulted in 15 quality measure statements. Among these, 5 met high consensus for importance and feasibility, including 2 on treatment and 3 on laboratory monitoring measures. The 3 highest‐ranked statements were recommended for further measure specification as SLE digital quality measures: 1) hydroxychloroquine use, 2) limiting glucocorticoid use >7.5 mg/day to <6 months, and 3) end‐organ monitoring of kidney function and urine protein excretion at least every 6 months.ConclusionThe Delphi process selected 3 quality measures for SLE care on hydroxychloroquine, glucocorticoid reduction, and kidney monitoring. Next, measures will undergo specification and validity testing in RISE and US rheumatology practices as the foundation for national implementation and use in quality improvement programs.image

show abstract

Management and treatment of glomerular diseases (part 2): Conclusions From A Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference

Cited by 27 publications

References 221 publications

KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases

KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases

Consensus Treatment Plans for Severe Pediatric Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

Development of American College of Rheumatology Quality Measures for Systemic Lupus Erythematosus: A Modified Delphi Process With Rheumatology Informatics System for Effectiveness (RISE) Registry Data Review

Contact Info

Product

Resources

About